Before 1990, a patient relapsing with chronic myeloid leukemia (CML) after an allogeneic bone marrow transplant (BMT) had two options: go back to interferon (IFN) or hydroxyurea (HU), or have a second transplant. Survival in our experience for 12 CML patients, grafted in chronic/accelerated phase , from an HLAidentical sibling before 1990, alive on day 100, and relapse was 53% at 10 years (unpublished). In 1990, donor lymphocyte infusions (DLIs) were introduced, adding a third option for patients who relapsed: in our experience this was beneficial, since survival of 46 CML patients grafted beyond 1990, alive on day 100, relapsing and given DLI is now 70% at 10 years. In multicenter studies, results have been less favorable: in a recent analysis, Guglielmi et al 1 studied 500 CML patients who relapsed before July 1996: survival for patients with no risk factors (less than 2 years from diagnosis, first chronic phase, cytogenetic relapse or chronic phase at relapse, time from transplant to relapse of less than 1 year and HLA-identical sibling transplant) was 42% at 10 years.
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In this issue of Leukemia, Olavarria et al 2 have reported a series of CML patients, who relapsed after an allograft and were treated with imatinib mesylate. Almost 50% were given imatinib as second-line therapy, after failing DLI. Nevertheless, 50% had a complete cytogenetic response and 25% a complete molecular response. There was no risk of graft-versus-host disease. Survival for patients with cytogenetic relapse of chronic phase relapse is 100%. Therefore, patients with CML relapsing after an allograft now have a fourth treatment option. It will be interesting to see how escalating dose DLI and imatinib can be optimized to produce maximum benefit with minimal toxicity. This may also open trials involving reduced intensity conditioning regimen, with very low mortality (less than 5%) and posttransplant prevention and treatment of relapse with imatinib and cells.
